Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4881098 | 0.86 | DYRK1A (0.48) | KDM4ECYP2C19MALT1NOTUMKMT2A | |
| SCHEMBL4879872 | 0.85 | KDM4E (0.60) | KDM4ECYP2C19MALT1L3MBTL1NOTUM | |
| SCHEMBL27684344 | 0.82 | MALT1 (0.48) | KDM4EMALT1TRPV1 | |
| SCHEMBL4880417 | 0.80 | PDE10A (0.39) | MALT1KMT2ATRPV1 | |
| SCHEMBL27684343 | 0.77 | MALT1 (0.41) | MALT1KMT2ATRPV1 | |
| SCHEMBL21384360 | 0.75 | TRPV1 (0.51) | KDM4ETDP1KMT2ATRPV1ALDH1A1 | |
| SCHEMBL28449100 | 0.74 | KDM4E (0.68) | KDM4ECYP2C19NOTUMKMT2AALDH1A1 | |
| SCHEMBL4778176 | 0.74 | MALT1 (0.34) | MALT1TRPV1 | |
| SCHEMBL4880388 | 0.73 | ALDH1A1 (0.44) | KDM4EMALT1RECQLALDH1A1 | |
| SCHEMBL1728915 | 0.73 | KMT2A (0.50) | KDM4ECYP2C19MALT1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| CN-101052625-A | As P2X7Adamantyl derivatives of receptor antagonists | ASTRAZENECA AB (SE) | 2007-10-10 | — | — | CN | disclosed |
| EP-1786786-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | AstraZeneca AB (SE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006025783-A1 | ADAMANTYL DERIVATES AS P2X7 RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | KDM4E 4115/4885CYP2C19 1390/4885MALT1 3949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.